Items tagged with Research and development

Media coverage of the 70th World Health Assembly (post)

Intellectual Property Watch news coverage of the 70th World Health Assembly:

Incentivizing antibiotic drug development to address antimicrobial resistance (post)

Experts agree that there is a need for a steady stream of innovation to address the constantly increasing rate of antimicrobial resistance. In a session entitled, “Bridging the ‘Valley of Death,’” the speakers described the gaps in antimicrobial development and discussed how government and private industry are working to address these gaps in antimicrobial drug development.

MSF urges G20 to take action on health issues (post)

Ahead of the G20 Summit in Hamburg, where global health is on the agenda for the first time, the international medical humanitarian organisation Médecins Sans Frontières (MSF) called on G20 leaders to follow through on the declaration made by their health ministers in late May.

Report says U.S. government must make strategic domestic, global investments to address TB (post)

3P Project enables radical change in R&D for TB treatment (post)

A new project that stimulates the development of affordable and effective drug regimens to treat tuberculosis (TB) is catching notice in policy circles.

The Union welcomes BRICS summit statement supporting R&D innovations such as the ‘3P Project' (post)

The Union welcomes the statement from the 9^th annual BRICS summit (PDF 484 KB) affirming a commitment to foster and promote R&D that will ensure access to quality, affordable medicines, and to support up-coming high level meetings on tuberculosis (TB). The BRICS summit was held in Xiamen, China on 3-5 September.

Immunocore and the Bill & Melinda Gates Foundation collaborate to develop immunotherapies for infectious diseases (post)

$40 million investment to accelerate development of Immunocore’s ImmTAV® and ImmTAB® therapeutics for infectious diseases, in particular tuberculosis and HIV

Where are the innovations in tuberculosis drug discovery? (post)

WHO has released a report that highlights a serious lack of antibiotics in clinical development; a worrying finding in an era of antimicrobial resistance. The report identifies a particular shortage of antibiotics under development for multidrug-resistant tuberculosis, which is a disease that kills a quarter of a million people every year.

TB Alliance moves two novel TB drugs into human trials (post)

GUADALAJARA (10 October, 2017) — TBA-7371 and sutezolid entered phase 1 clinical trials, TB Alliance announced today. Both compounds have proceeded through early preclinical development and were granted “Investigative New Drug” status by the U.S. Food and Drug Administration. The phase 1 clinical trials are presently ongoing. 

TBVAC2020 review article now online (post)

TBVAC2020 (a European consortium of TB R&D partners led by TBVI and funded by the EC) gives an update on its progress towards the development of new, safe and affordable TB vaccines – essential to control the TB epidemic and combat AMR.